Citi analyst David Lebowitz lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $29.00 (from $31.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE